Hosted on MSN1mon
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.
Hosted on MSN1mon
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.
MarketWatch1mon
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy ... two oral antidepressants. The FDA in 2019 approved Spravato, a close ...
Healio11d
FDA approves epinephrine nasal spray for children aged as young as 4 years
Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...
Yahoo Finance1mon
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ...
NBC Connecticut1mon
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.